Ovarian cancer patient is first to receive new therapy targeting Mage-A4 protein

Key facts

• Tracy Tomlinson, a 58-year-old ovarian cancer patient, received a new therapy.
• She is the first patient globally to receive the ZI-MA4-1 therapy.
• The therapy targets the Mage-A4 protein.
• The treatment was administered at the Christie NHS Foundation Trust in Manchester.
• The therapy is part of a clinical trial.
• The treatment engineers T-cell receptors to target tumors producing Mage-A4 protein.

Tracy Tomlinson, a 58-year-old patient diagnosed with ovarian cancer, has made history as the first individual globally to receive a new experimental therapy targeting the Mage-A4 protein. The treatment, designated ZI-MA4-1, was administered at the Christie NHS Foundation Trust located in Manchester. This groundbreaking therapy is currently part of a clinical trial aimed at developing innovative cancer treatments. The core mechanism of ZI-MA4-1 involves a sophisticated process of engineering a patient's T-cell receptors. These modified receptors are designed to specifically identify and bind to tumor cells that produce the Mage-A4 protein. By equipping the patient's own immune cells with this targeted capability, the therapy seeks to mount a more effective immune response against the cancer. The successful administration of this therapy to Tomlinson marks a significant milestone in the ongoing research and development of immunotherapies for various forms of cancer.